Focus: IO Biotech is a Copenhagen-based immuno-oncology biotech founded in 2012, focused on peptide-based cancer vaccines targeting PD-L1 and combination approaches. The company is public (IOBT) with a lean pipeline in Phase 1–3 development across multiple solid tumors.
Profile data last refreshed 7h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow IO Biotech to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from IO Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for IO Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
8-K Filing: Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070) — INVESTOR PRESENTATION OF SCANCELL HOLDINGS PLC, DATED JULY 2026
INVESTOR PRESENTATION OF SCANCELL HOLDINGS PLC, DATED JULY 2026
Cue lines up new CMO and research head—Chutes & Ladders - Fierce Biotech
Cue lines up new CMO and research head—Chutes & Ladders Fierce Biotech
Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire - Endpoints News
Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire Endpoints News
Elevara Medicines appoints biotech veteran as CEO - The Pharma Letter
Elevara Medicines appoints biotech veteran as CEO The Pharma Letter
Shortly after bankruptcy: IO Biotech founder takes on new top position - medwatch.com
Shortly after bankruptcy: IO Biotech founder takes on new top position medwatch.com
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers Fierce Biotech
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.
Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo